SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
LCTX

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE: LCTX · Real-Time Price · USD
Healthcare · Biotechnology
$0.80-$0.12 (-13.07%)
 
Market cap
$201M
Insider Score
Analyst consensus
Market Cap$201.12M-57.5%
Revenue (ttm)$10.84M
Net Income$1.75M
EPS-$0.10
Shares Out252.95M
PE Ration/a
Forward PE-7.23
Dividendn/a
Ex-Dividend Daten/a
Volume12,762,959
Open$0.94
Previous Close$0.91
Day's Range$0.77 - $0.95
52-Week Range$0.77 - $1.99
Beta1.69
AnalystsStrong Buy
Price Target$5.50(+591.74%)
Earnings DateNov 12, 2026

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Address
2173 Salk Avenue, Carlsbad, CA, 92008, United States
Market Cap
201 million
Employees
72
Industrial Classification
Biotechnology

Lineage Cell Therapeutics, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
62nd Percentile Overall Score
LCTX InsiderScore:76 / 99

Lineage Cell Therapeutics, Inc. scored higher than 62% of companies evaluated by InsiderBuying, and ranked 29th out of 101 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Lineage Cell Therapeutics, Inc. bought $17.1K of stock across 1 purchase in the last 90 days, the largest of them $17.1K.

Stake Increase

The average purchase added about 78% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$17.10K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-12.09%
5 Days
-25.93%
1 Month
-18.37%
6 Months
-35.48%
1 Year
-57.45%

$LCTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in LCTX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by LCTX's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

LCTX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New LCTX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to LCTX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from LCTX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
75.95
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$17.10K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.18%
IBBiShares Biotechnology ETF0.01%

Weight is the stock’s share of each fund’s holdings.